New drug combo aims to shrink tumors before breast cancer surgery

NCT ID NCT07162051

Summary

This study is testing whether adding a drug called fluzoparib to standard chemotherapy is safe and effective at shrinking tumors before surgery. It is for people with a specific type of early-stage breast cancer (HR+/HER2- and HRD-positive). The goal is to see if this combination leads to less cancer remaining after treatment, which may improve long-term outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xijing hospital

    RECRUITING

    Xi'an, Shaanxi, 710032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.